• Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

  NCT06181734

  CompletedObservationalUpdated Feb 10, 2026
• Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768

  Not yet recruitingInterventionalPhase 2Updated Mar 11, 2026
• a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

  NCT07007949

  RecruitingInterventionalPhase 2Updated Jun 6, 2025
• A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

  NCT04176393

  CompletedInterventionalPhase 1Updated Feb 13, 2023
• An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

  NCT05907057

  RecruitingInterventionalPhase 3Updated May 8, 2026
• Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

  NCT07607418

  RecruitingInterventionalPhase 2Updated May 26, 2026

ClinicalTrials.gov ID

NCT06377579

Lead Sponsor

French Innovative Leukemia OrganisationOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

250Estimated

Last Update Posted

Nov 26, 2025Actual

Start Date

Jul 31, 2024Actual

Primary Completion Date

Aug 30, 2025Actual

Completion Date

Jun 1, 2026Estimated

Official Title

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

Brief Summary

Mutations in IDH genes are found in numerous cancers and more specifically in acute myeloid leukemia (AML). These mutations target specific amino acids, at positions 140 or 172 of IDH2, and 132 of IDH1. Mutant IDH proteins acquire an abnormal enzymatic activity allowing them to convert α-ketoglutarate (αKG) into D-2 hydroxyglutarate (D-2HG), an oncometabolite which massively accumulates in IDH-mutated cells. At high levels, D-2HG behaves as a competitive inhibitor of αKG and affects the activity of Fe(II)/αKG-dependent dioxygenases. This enzymatic family is involved in a broad spectrum of pathways such as demethylation of histone (JHDM histone demethylases) or DNA (methylcytosine hydroxylases of the TET family). As a result, IDH-mutated cells show altered survival, motility, invasiveness and cell differentiation. In AML, IDH1 mutations might be present in 10-15% at diagnosis

Ivosidenib (IVO) a first-in-class, oral, irreversible inhibitor of mutant IDH1 has shown clinical activity as a single agent in studies involving patients with IDH1 mutated relapsed or refractory (R/R) AML and in front line settings. In phase II clinical trials, IVO yielded 30-35% of complete response rates both in frontline and R/R settings, with long lasting responses. Based on these results, the FDA (Food and Drug Agency) gave its approval for newly-diagnosed AML IDH1mut patients who are ≥ 75 years old or who have comorbidities and in R/R. However, European Medicines Agency (EMA)'s did not approved IVO due to lack of evidences to support the application. Agios Netherlands B.V. (the company that previously own the drug before Servier Laboratories) withdrew its EMA application. Nevertheless, IVO has been available in France through a compassionate use program (CUP), since February 2020 for R/R patients and March 2022 for first line treatment.

In this multicentric retrospective study, sponsor aim to evaluate the efficacy and safety of Ivo in two cohorts of IDH1mut AML patients treated within the CUP. The first cohort will concern patients treated in first line setting and the second cohort those treated in R/R disease. Results might provide new insights regarding IVO in real life settings and support signs of efficacy. This could provide new data for the haematologist community and for another appliance to grant EMA approval of IVO in the setting of R/R IDH1mut AML.

• AML, Adult

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patient with IDH1 R132 mutated with newly diagnosed or Relapsed or Refractory (R/R) acute myeloid leukemia
• Patient treated within French compassionate access program that have started the treatment between 01/01/2017 to 01/08/2023
• patient treated by Ivosidenib received either as a monotherapy or in combination with other AML therapy (i.e. azacytidine, venetoclax)
• Patient not included within IDH inhibitor clinical trial.

Exclusion Criteria:

• Patients who expressed their opposition to entered in the study
• Patients who received IVO through a trial

Observational Model

Cohort

Time Perspective

Cross-Sectional

Lead Sponsor

French Innovative Leukemia OrganisationOTHER

Collaborators

Acute Leukemia French AssociationOTHER

pierre.peterlin@chu-nantes.fr

cluzeau.t@chu-nice.fr